Bifogade filer
CombiGene Q2 2023 EN
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
April – June 2023
• Net sales: TSEK 1,788 (4,738).
• Other operating revenues: TSEK 1,413 (9,800).
• Profit from financial items: TSEK -6,286 (4,516).
• Earnings per share: SEK -0.32 (0.23).
January – June 2023
• Net sales: TSEK 3,955 (16,141).
• Other operating revenues: TSEK 543 (12,602).
• Profit from financial items: TSEK -20,903 (1,832).
• Earnings per share: SEK -1.06 (0.09).
• Cash and cash equivalents: TSEK 115,442 (125,953).
Events during the period
• Gene Therapy, one of Nature’s journals, publishes an article about CombiGene’s epilepsy project authored by Esbjörn Melin, scientist at CombiGene.
• High activity level in the pain program COZY in preparation of the final preclinical toxicology program in the peptide project COZY01.
• CombiGene to play an integral part in the development of a national infrastructure for ATMPs. CombiGene’s CEO Jan Nilsson elected Chairman of the Board of CCRM Nordic AB.
• CombiGene forms prominent Scientific Advisory Board within the pain program COZY.
• Jan Nilsson leaves his position as CEO of CombiGene – COO Peter Ekolind takes over as new CEO on September 1, 2023.
Events after the end of the period
• There have been no significant events after the end of the period.